Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Diabetes isn't just costing Indians their lifelong savings, it's also costing the country INT11.4 trillion.

According to a Nature Medicine study, India faces the second highest economic burden due to this chronic condition. Only the United States ranks higher, with costs touching INT 16.5 trillion, while China comes in third at INT 11 trillion.

While excluding informal care provided by family members, the global costs comes around INT 10 trillion which is about 0.2 per cent of the world’s annual gross domestic product (GDP).

However, if informal care is factored in, costs goes up to INT152 trillion or 1.7 per cent of the world’s yearly GDP, as per the study. (An international dollar, or INT$, is a statistical unit that has the same purchasing power as a US dollar).

The scientists estimated that the economic impact of diabetes was much more than Alzheimer’s disease or cancer in the top three countries.

The Diabetes Crisis In India

Diabetes is a chronic condition affecting several aspects of physical and mental health. It occurs when either the body can’t make enough insulin or can’t use it effectively, which impairs several functions.

Often referred to as the 'Diabetes capital of the world', over 100 million people across India suffer from the chronic condition while another 136 million are living with prediabetes.

According to Pharmeasy 2025 Diabetes Report, one in two people show high blood sugar levels when tested and over 90 percent of reports with high blood sugar also showed abnormality in one or the other parameters for liver, lipid, heart or thyroid issues.

Also known as a 'Silent Killer', diabetes can develop and progress quietly in the body, often without clear or early symptoms. Multiple studies show that over 50 percent of people with diabetes in India are undiagnosed or unaware of their condition.

When left undiagnosed and untreated, diabetes can cause severe complications across the body including heart disease, kidney damage or vision loss. These complications disproportionately affect vulnerable parts of the population, especially those in rural areas without access to proper testing and treatment.

Despite the growing economic burden, India faces systemic challenges in addressing diabetes, including inadequate healthcare infrastructure, low public awareness and fragmented policy responses.

What Did The Study Find?

They evaluated costs based on medical expenses, productivity losses and caregiving.

While the burden in the US is largely due to high treatment costs and loss of physical capital, the high costs are mainly driven by the sheer number of people affected in India and China, the researchers said.

Author Klaus Prettner, professor of macroeconomics and digitalization at the Vienna University of Economics and Business noted of the results: "Caregivers often drop out of the labor market, at least partially, which creates additional economic costs."

"This is a stark illustration of how medical treatment regimes for chronic diseases such as diabetes are accessible to high income countries only," co-author Michael Kuhn, acting economic frontiers research group leader at the International Institute for Applied Systems Analysis, added.

Based on the results, the scientists said promoting healthier lifestyle, regular physical activity and a balanced diet is the most effective way to prevent diabetes and reduce its economic impact in each country in the long run.

Colleen Hoover, the best-selling author of 'Regretting You' and 'Verity', has revealed that she has undergone treatment for cancer.

On January 12, Hoover announced via her Instagram Stories that she has one more day of radiation left at Texas Oncology.

"Second to last day of radiation," she captioned the post on her Instagram Stories. "I wish I could blame my hair and facial expressions on @Texas.Oncology, but they've been great. Hope you never need them, but highly recommend them."

In December 2025, the 46-year-old writer wrote on her Facebook page that she had been diagnosed with cancer and had undergone surgery. The film producer also noted that she would only need radiation, but not chemotherapy as a treatment plan.

Hoover said she had been in Canada filming Reminds of Him when she noticed she “had recurring health issues that I continued to put off until the movie was finished" and a check-up revealed that she had developed cancer.

What Kind Of Cancer Does She Have?

While she is yet to reveal which kind of cancer she is receiving treatment for, Hoover has confirmed it was not caused by family genes, HPV or excessive hormones.

In a Facebook post from January 9, she noted that the reason for her illness is 'more than likely' to be environmental/lifestyle, which can be credited to a lack of exercise, poor diet and stress.

"I’m happy and grateful to be alive but I hate vegetables. I hate when I have to get off the couch. I hate sweating. I hate when science is right. If you see me at the gym, don’t even tell me good job. If you see me at a restaurant eating grilled chicken and drinking water, I’m probably real mad about it," she wrote in a heartfelt moment.

Why Has Hoover Been Missing From Public Eye?

Hoover's health updates and cancer treatment come amid a series of cancelled public events. In October 2025, she announced she would not attend the premiere of Regretting You, her latest movie adaptation.

In a sentimental Instagram post, she told her fans: "I’m super bummed, but am having an unavoidable surgery and can’t travel for a while,” Hoover wrote in her Instagram post at the time. I’ll live vicariously through you guys. So sad to miss this movie release and premiere, but so grateful to all the actors and the team who put this together.”

Woman Down is Hoover’s next book release set for January 13. However, the author has had to tell fans that a book-signing tour has not been set up yet and she will not be meeting with the public for now.

“I wanted to make this post and be transparent about why that is. I’m not saying I won’t be up to doing at least one signing, but I just won’t know until I know," she said.

Meanwhile, throughout 2025, production on her hit novel, Verity, has begun in 2025, with Anne Hathaway and Josh Hartnett, being photographed during scenes last February. Additionally, her third movie adaptation, Reminders of Him, is also set to hit theaters on March 13, 2026.

It remains unknown if she will be attending the premiere for Reminders of Him.

Barbie. A name too familiar for everyone growing up, now Mattel Studio has launched its first autistic Barbie. This is after Greta Gerwig's 2023 blockbuster movie that introduced the concept of diverse characters of Barbie, that Mattel launched its first Barbie with type 1 diabetes. The studio is definite about creating a diverse range of Barbie character, as an animated Barbie film too is in the development.

Why Is The Launch Of Autistic Barbie Important?

Autistic Barbie is the latest addition to Barbie's Fashionistas range, which is designed so more children can "see themselves in Barbie". The Barbie is created in collaboration with the US charity the Autistic Self Advocacy Network. The Barbie is designed to represent the ways autistic children may have experienced, including the way they communicate.

Barbie With Autism: What Are Her Features?

The Barbie's eyes gaze slightly to one side, which could represent how some autistic people avoid direct eye contact. The Barbie also comes with completely bendable elbows and wrists, which enables her repetitive physical movements such as stimming and hand-flapping that help people with autism to process sensory information, or even express excitement.

She also holds a pink fidget spinner on her finger, which helps her reduce her stress, wears noise-cancelling headphones, also in pink, to reduce sensory overload, and carries a pink tablet with symbol-based augmentative and alternative communication buttons on its screen that helps with her everyday communication.

Barbies earlier came in one-size-fit-all, often lacking the diversity and representation, this Barbie, however, wears a loose-fitting purple pinstripe A-line dress. This has minimized fabric to skin contact, and her shoes have flat soles that promotes stability and ease of movements.

Read: Hundreds Of US Children Have Type 1 Diabetes, Now Their Barbie Has It Too

Barbie's Representation Matters

The first Barbie came in 1959, and until 2019, there were no dolls with disabilities. Now, there are Barbies with diabetes, blind dolls, and Barbies with wheelchairs, Down syndrome, prosthetic limb, vitiligo, and hearing aids. There is also a Ken doll with a prosthetic leg, and another one who uses a wheelchair with a ramp, and one with hearing aids.

Jamie Cygielman, the global head of dolls at Mattel while announcing the autistic Barbie said, "Barbie has always strived to reflect the world kids see and the possibilities they imagine, and we’re proud to introduce our first autistic Barbie as part of that ongoing work. The doll helps to expand what inclusion looks like in the toy aisle and beyond because every child deserves to see themselves in Barbie."

She also added: “We engaged with the autistic community throughout the design process, always mindful that autism is experienced differently by every individual and is not always visible. The elements of this doll reflect how some people on the spectrum may experience and express the world, and we hope that by partnering with influential voices within the community, Barbie can continue to showcase a broader range of authentic experiences.”

What Is Autism?

As per the American Psychiatric Association, ASD is a complex developmental condition involving persistent challenges with social communication, restricted interests and repetitive behavior. While autism is considered a lifelong condition, the need for services and supports because of these challenges varies among individuals with autism.

As per the Centers for Disease Control and Prevention, an estimated one in 36 children have been identified with ASD.